REGENXBIO, Inc. (RGNX)

Over the past six months, REGENXBIO's stock price has increased. Key events impacting the stock price include Q3 2025 earnings, positive RGX-202 data, a regulatory update on MPS programs with a clinical hold, and a PDUFA date for RGX-121. The FDA placed a clinical hold on REGENXBIO's investigational gene therapy RGX-111 for MPS I, following a preliminary analysis of a single case of neoplasm in a participant. The FDA also placed a clinical hold on RGX-121 for MPS II, citing similarities in products, study populations, and shared risk.

There is no explicit indication of demand seasonality for REGENXBIO's gene therapy products and services. Demand is primarily driven by disease prevalence, clinical trial outcomes, regulatory approvals, and patient access.

REGENXBIO Inc. is a clinical-stage biotechnology company focused on gene therapy, utilizing its NAV Technology Platform to develop treatments for genetic defects. Its pipeline includes product candidates targeting rare and retinal diseases such as RGX-314 for wet AMD and diabetic retinopathy, RGX-202 for Duchenne muscular dystrophy, RGX-121 for MPS II, and RGX-111 for MPS I.

REGENXBIO Inc. is based in the United States, with its principal offices and Manufacturing Innovation Center in Rockville, Maryland. Its talent footprint is mainly in the Maryland/DC biotechnology corridor, with some remote staff. The majority of the company's revenue is derived from the United States.

REGENXBIO generally holds a positive brand reputation among analysts, with a consensus "Buy" rating. Positive clinical trial results and strong manufacturing capabilities have enhanced investor confidence. However, the clinical hold on MPS programs and concerns about manufacturing capacity and data delays could negatively impact the company's reputation.

REGENXBIO Inc. has substantial institutional ownership, with over 50% of the company's stock held by institutional investors. Major institutional shareholders include BlackRock, Inc., Redmile Group, LLC, and JPMorgan Chase & Co. Individual ownership includes Allan Fox and CEO Kenneth Mills.